A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

PURPOSE: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Seventy-one patients received oral TAK-117 once daily...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Juric, Dejan, de Bono, Johann S., LoRusso, Patricia M., Nemunaitis, John, Heath, Elisabeth I., Kwak, Eunice L., Mercadé, Teresa Macarulla, Geuna, Elena, Jose de Miguel-Luken, Maria, Patel, Chirag, Kuida, Keisuke, Sankoh, Serap, Westin, Eric H., Zohren, Fabian, Shou, Yaping, Tabernero, Josep
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858996/
https://ncbi.nlm.nih.gov/pubmed/28490463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2888
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires